Amicus Therapeutics, Inc. (FOLD)
USD 9.57
(-3.24%)
USD 9.57
(-3.24%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 399.35 Million | 329.23 Million | 305.51 Million | 260.88 Million | 182.23 Million | 91.24 Million |
| Cost of Revenue | 37.32 Million | 38.59 Million | 34.46 Million | 31.04 Million | 21.96 Million | 14.4 Million |
| Gross Profit | 362.03 Million | 290.63 Million | 271.04 Million | 229.84 Million | 160.27 Million | 76.84 Million |
| Operating Expenses | 427.65 Million | 495.06 Million | 470.96 Million | 473.69 Million | 461.01 Million | 402.31 Million |
| Selling, General and Administrative Expenses | 275.27 Million | 213.04 Million | 192.71 Million | 156.4 Million | 169.86 Million | 127.2 Million |
| Research and Development Expenses | 152.38 Million | 276.67 Million | 272.04 Million | 308.44 Million | 286.37 Million | 270.9 Million |
| Other Expenses | - | 5.34 Million | 6.2 Million | 8.84 Million | 4.77 Million | -5.63 Million |
| Cost and Expenses | 472.85 Million | 533.65 Million | 505.43 Million | 504.74 Million | 482.97 Million | 416.72 Million |
| Operating Income | -73.49 Million | -204.42 Million | -199.92 Million | -243.85 Million | -300.74 Million | -328.77 Million |
| Interest Expense | 50.14 Million | 37.11 Million | 32.47 Million | 22.42 Million | 18.87 Million | 22.4 Million |
| Income Tax Expense | 1.48 Million | -5.47 Million | 8.9 Million | 2.59 Million | 478 Thousand | -94 Thousand |
| Earnings before Tax | -150.1 Million | -242.03 Million | -241.55 Million | -274.25 Million | -355.91 Million | -349.08 Million |
| Net Income | -151.58 Million | -236.56 Million | -250.46 Million | -276.85 Million | -356.38 Million | -348.99 Million |
| Earnings Per Share Basic | -0.51 | -0.82 | -0.92 | -1.07 | -1.48 | -1.88 |
| Earnings Per Share Diluted | -0.51 | -0.82 | -0.92 | -1.07 | -1.48 | -1.88 |
| Weighted Average Shares Outstanding | 295.16 Million | 289.05 Million | 271.42 Million | 258.86 Million | 240.42 Million | 185.79 Million |
| Weighted Average Shares Outstanding (Diluted) | 295.16 Million | 289.05 Million | 271.42 Million | 258.86 Million | 240.42 Million | 185.79 Million |
| Gross Margin | 0.91 | 0.88 | 0.89 | 0.88 | 0.88 | 0.84 |
| EBIT Margin | -0.23 | -0.58 | -0.64 | -0.89 | -1.81 | -3.47 |
| Profit Margin | -0.38 | -0.72 | -0.82 | -1.06 | -1.96 | -3.82 |
| EBITDA | -92.07 Million | -199.57 Million | -202.87 Million | -242.98 Million | -332.26 Million | -322.47 Million |
| Earnings Before Tax Margin | -0.18 | -0.62 | -0.65 | -0.93 | -1.65 | -3.60 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 126.66 Million | 110.4 Million | 399.35 Million | 115.08 Million | 103.5 Million | 94.5 Million |
| Cost of Revenue | 13.44 Million | 15.72 Million | 45.19 Million | 13.5 Million | 9.94 Million | 9.11 Million |
| Gross Profit | 113.22 Million | 94.68 Million | 354.15 Million | 101.57 Million | 93.55 Million | 85.38 Million |
| Operating Expenses | 98.25 Million | 116.35 Million | 427.65 Million | 105.26 Million | 106.35 Million | 102.77 Million |
| Selling, General and Administrative Expenses | 73.57 Million | 88.02 Million | - | 70.23 Million | 65.65 Million | 65.42 Million |
| Research and Development Expenses | 24.68 Million | 28.32 Million | - | 35.02 Million | 40.7 Million | 35.14 Million |
| Other Expenses | -3.71 Million | -4.96 Million | -15.88 Million | -2.87 Million | 3.83 Million | -10.9 Million |
| Cost and Expenses | 111.7 Million | 132.07 Million | 472.85 Million | 118.77 Million | 116.3 Million | 111.89 Million |
| Operating Income | 14.96 Million | -21.67 Million | -73.49 Million | -3.69 Million | -17.02 Million | -18.86 Million |
| Interest Expense | 12.51 Million | 12.43 Million | 50.14 Million | 12.82 Million | -12.98 Million | 12.49 Million |
| Income Tax Expense | 15.8 Million | 4.83 Million | 1.48 Million | 2.18 Million | 3.12 Million | 2.71 Million |
| Earnings before Tax | 108 Thousand | -43.58 Million | -150.1 Million | -31.66 Million | -24.7 Million | -40.51 Million |
| Net Income | -15.69 Million | -48.41 Million | -151.58 Million | -33.84 Million | -21.57 Million | -43.23 Million |
| Earnings Per Share Basic | -0.05 | -0.16 | - | -0.12 | -0.07 | -0.15 |
| Earnings Per Share Diluted | -0.05 | -0.16 | - | -0.12 | -0.07 | -0.15 |
| Weighted Average Shares Outstanding | 303.77 Million | 302.9 Million | 295.16 Million | 293.59 Million | 295.75 Million | 292.79 Million |
| Weighted Average Shares Outstanding (Diluted) | 303.77 Million | 302.9 Million | 295.16 Million | 293.59 Million | 295.75 Million | 292.79 Million |
| Gross Margin | 0.89 | 0.86 | 0.89 | 0.88 | 0.90 | 0.90 |
| EBIT Margin | 0.14 | -0.18 | - | -0.01 | -0.28 | -0.26 |
| Profit Margin | -0.12 | -0.44 | -0.38 | -0.29 | -0.21 | -0.46 |
| EBITDA | 17.14 Million | -19.52 Million | - | -1.51 Million | -29.2 Million | -24.34 Million |
| Earnings Before Tax Margin | 0.12 | -0.20 | -0.18 | -0.03 | -0.16 | -0.20 |
MLYF
2390
DWWEF
MLCAC
603286
RKDL